The failure of intensive medication to halt beta-cell decline in children with early type 2 diabetes occurs despite them having better baseline beta-cell and alpha-cell function than newly diagnosed adults, say the RISE researchers.
Findings from the NewLira trial suggest that addition of the glucagon-like peptide-1 receptor agonist liraglutide to insulin treatment may preserve postprandial insulin secretion among adults with newly diagnosed type 1 diabetes.
The CKD273 proteomic biomarker panel can predict which people with type 2 diabetes will develop detectable diabetic nephropathy, but early intervention with spironolactone does not mitigate this risk, report the PRIORITY investigators.
Treatment with the interleukin-1 inhibitor anakinra improves both glycemic and inflammatory endpoints among patients with rheumatoid arthritis and type 2 diabetes, suggest findings from the TRACK trial.
Imeglimin, an agent that improves mitochondrial function, has demonstrated potential as a novel treatment option for Japanese patients with type 2 diabetes in the phase III TIMES 1 and TIMES 3 trials.
Findings from the SUSTAIN 10 trial show that semaglutide results in better glycemic control than liraglutide when added to oral antidiabetic drugs in people with type 2 diabetes.
Treatment with the glucagon-like peptide-1 receptor agonist semaglutide results in better glycemic control than the sodium-glucose cotransporter 2 inhibitor canagliflozin among people with type 2 diabetes uncontrolled on metformin, indicate the SUSTAIN 8 trial results.
Upfront combination therapy with vildagliptin and metformin is more durable than metformin alone, and appears to have a legacy effect, report the VERIFY investigators.
The limitations of a clinical trial of gamma aminobutyric acid on the progression of newly diagnosed type 1 diabetes may have precluded any positive results, say the researchers.
Ten-year results from the Beijing Community Diabetes Study indicate that collaborative care delivered by primary care providers and specialists may result in sustained improvements in cardiovascular risk factor control among people with type 2 diabetes.
Researchers at the 55th EASD Annual Meeting in Barcelona, Spain, have presented primary data and subanalyses from a number of the PIONEER trials investigating the efficacy of oral semaglutide in people with type 2 diabetes.
The COMISAIR-2 researchers have reported that use of continuous glucose monitoring by people with type 1 diabetes remains high over 3 years, resulting in continued glycemic benefits.
A systematic review in The BMJ suggests the incidence of diabetes may be falling in many countries, with researchers suggesting preventive strategies may be proving effective.
Results of the DEFINE-HF trial indicate that add-on dapagliflozin treatment may improve health status among people with established heart failure and reduced ejection fraction.
Adherence to first-line diabetes medication, ascertained from prescription records, is the only routine clinical variable that is a strong indicator of people’s adherence to second-line treatment, say researchers.
Short-term structured strength and balance training does not improve quality of life in patients with type 2 diabetes-related peripheral neuropathy, but may increase functional status and balance confidence, research shows.
Researchers have identified factors that predict repeated very low blood sugar among adults with type 1 diabetes who have suboptimal awareness of hypoglycemia.